Mode
Text Size
Log in / Sign up
N/A N=25

The Role of Oxidative Stress in the Cardiovascular Consequences of Sleep Apnea

Sleep Apnea

Enrolled (actual)
25
Serious AEs
0.0%
Results posted
Oct 2013
Primary outcome: Primary: Flow Mediated Dilation — 5.7; 9.5; 7.3 percentage change of vessel diamter — p=0.02

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Rami Khayat
Primary completion
Jun 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Flow Mediated Dilation
5.7; 9.5; 7.3 0.02 sig

Summary

Obstructive Sleep Apnea (OSA) is the most common sleep disorder affecting up to 9-24 percent of middle aged adults, and is becoming increasingly implicated in the pathogenesis of hypertension, and other cardiovascular disorders. Up to half of patients with OSA have hypertension, and their risk of developing hypertension increases with the increasing severity of Sleep Apnea. Patients with OSA and no hypertension have endothelial dysfunction, which is believed to be the precursor for most cardiovascular disorders. The upper airway collapse and obstruction that occur in OSA result in a pattern of intermittent hypoxia, that has been shown to be the cause of the hypertension, and endothelial dysfunction found in patients with OSA. Intermittent hypoxia results in oxidative stress, which in turn is linked to the pathogenesis of hypertension and endothelial dysfunction. This protocol evaluates the role of the oxidative stress in endothelial function and blood pressure in patients with OSA. This is a pilot clinical study that will compare oxidative stress parameters, and endothelial function in patients with OSA before starting treatment with continuous positive airway pressure (CPAP) and 12 weeks post being on CPAP. These patients will be compared to control patients with no history of OSA. the study does not involve assignement to different treatments. All patients will receive the indicated treatment for OSA and measurements will be collected before and 12 weeks after adequate treatment.

Eligibility Criteria

Inclusion Criteria

  • Completed sleep study - Older than 18

Exclusion Criteria

  • Hypertension
  • Diabetes
  • coronary disease
  • Peripheral vascular disease
  • High cholesterol
  • Smoking
  • Pregnancy
  • Use of erectile dysfunction medications or supplements
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00701441). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search